Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9Y4K0

UPID:
LOXL2_HUMAN

ALTERNATIVE NAMES:
Lysyl oxidase-like protein 2; Lysyl oxidase-related protein 2; Lysyl oxidase-related protein WS9-14

ALTERNATIVE UPACC:
Q9Y4K0; B2R5Q0; Q53HV3; Q9BW70; Q9Y5Y8

BACKGROUND:
The enzyme Lysyl oxidase homolog 2 (LOXL2) is integral to the cross-linking of extracellular matrix proteins, mediating oxidative deamination of peptidyl lysine residues. This action is essential for the structural integrity of collagen and elastin. Beyond its structural role, LOXL2 is involved in transcriptional repression through deamination of specific histone and non-histone proteins, influencing gene expression patterns critical for embryonic stem cell pluripotency and EMT. Its interaction with SNAI1 and role in hypoxia-induced E-cadherin repression highlight its importance in cellular differentiation and tumor aggressiveness.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Lysyl oxidase homolog 2 could open doors to potential therapeutic strategies. Given its involvement in critical processes such as EMT and its regulatory role in the extracellular matrix, targeting LOXL2 could provide new avenues for treating a range of conditions, from fibrotic diseases to cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.